Does Ledipasvir And Sofosbuvir Interact with Doravirine Lamivudine And Tenofovir Disoproxil Fumarate?
CDI records a moderate classification for Ledipasvir And Sofosbuvir and Doravirine Lamivudine And Tenofovir Disoproxil Fumarate. The stored summary is: Co-administration increases tenofovir plasma concentrations. Monitor for adverse reactions associated with tenofovir disoproxil fumarate. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Ledipasvir And Sofosbuvir Class
- Hepatitis C Virus NS5A Inhibitor
- Doravirine Lamivudine And Tenofovir Disoproxil Fumarate Class
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
What To Tell Your Doctor or Pharmacist
If you are taking Ledipasvir And Sofosbuvir and your doctor is considering prescribing Doravirine Lamivudine And Tenofovir Disoproxil Fumarate (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider